The Samsung Biologics labor union began its first full-scale strike this week, with the walkout scheduled to last five days [1].
This labor action marks a significant escalation in tension at one of South Korea's largest biotech firms. The strike threatens production stability and financial performance for a company with a market capitalization of 68 trillion won [1].
Approximately 2,800 union members are participating in the strike [1]. The union said the action is a result of management’s decision-making failures and unresolved disputes over wage increases [1, 2]. These tensions persist despite 13 rounds of negotiations that began in December 2023 [1, 2].
The union claims the five-day stoppage will cause the company to incur a loss of 640 billion won [2]. This figure represents a substantial hit to the company's operations, which generate 4 trillion won in revenue [1].
Efforts to prevent the walkout occurred shortly before the strike began. A reporter for YTN said that management and labor held town hall meetings and sought mediation through the labor office, but these efforts failed to stop the strike [1].
Union representatives said the company must enter negotiations immediately [1]. The current labor unrest is not isolated to the biologics division, as the Samsung Electronics union is also planning a strike [1, 2].
“The strike runs until the 5th of the month.”
The coordinated labor unrest across Samsung's biologics and electronics divisions suggests a systemic breakdown in labor-management relations within the conglomerate. If the Samsung Electronics union follows through with its own strike, the combined impact could disrupt global supply chains and signal a shift in the bargaining power of South Korean tech and biotech workers.
